Cookie Policy: This site uses cookies to improve your experience. You can find out more about our use of cookies in our Privacy Policy. By continuing to browse this site you agree to our use of cookies.
AdipoGen Life Sciences
ACY-775
180
CHF
CHF 180.00
In stock
AG-CR1-3903-M0011 mgCHF 180.00
AG-CR1-3903-M0055 mgCHF 640.00
| Product Details | |
|---|---|
| Synonyms | 2-((1-(3-Fluorophenyl)cyclohexyl)amino)-N-hydroxypyrimidine-5-carboxamide |
| Product Type | Chemical |
| Properties | |
| Formula |
C17H19FN4O2 |
| MW | 330.4 |
| CAS | 1375466-18-4 |
| Purity Chemicals | ≥95% (HPLC) |
| Appearance | Off white solid. |
| Solubility | Soluble in DMSO, methanol or ethanol. |
| Identity | Determined by 1H-NMR. |
| InChi Key | IYBURCQQEUNLDL-UHFFFAOYSA-N |
| Smiles | ONC(=O)C1=CN=C(NC2(CCCCC2)C2=CC(F)=CC=C2)N=C1 |
| Shipping and Handling | |
| Shipping | AMBIENT |
| Short Term Storage | +4°C |
| Long Term Storage | -20°C |
| Handling Advice |
Keep cool and dry. Protect from light. |
| Use/Stability | Stable for at least 2 years after receipt when stored at -20°C. |
| Documents | |
| MSDS |
 Download PDF |
| Product Specification Sheet | |
| Datasheet |
Download PDF |
Description
- Cell permeable, potent and selective class IIb HDAC6 inhibitor (IC50 =7.5nM). Displays high selectivity over HDAC1-9 (IC50=1-10µM).
- Shows improved brain bioavailability compared to tubastatin A (Prod. No. AG-CR1-3900).
- Induces hyperacetylation of α-tubulin in brain without concurrently altering the acetylation of histones.
- Shows antidepressant activity.
- HDAC6 deacetylates tubulin, HSP90 and the core histones (H2A, H2B, H3, H4). Histone deacetylases act via the formation of large multiprotein complexes. HDAC6 plays an important role in microtubule-dependent cell motility, transcriptional regulation, degradation of misfolded proteins and cell cycle and is involved in autophagy, inflammation, cancer and neurodegeneration.
Product References
- Histone deacetylase (HDAC) inhibitors as single agents induce multiple myeloma cell death principally through the inhibition of class I HDAC: S. Mithraprabhu, et al.; Br. J. Haematol. 162, 559 (2013)
- Prognostic and therapeutic relevance of FLIP and procaspase-8 overexpression in non-small cell lung cancer: J.S. Riley, et al.; Cell Death Dis. 4, e951 (2013)
- RPL24: a potential therapeutic target whose depletion or acetylation inhibits polysome assembly and cancer cell growth: K.A. Wilson-Edell, et al.; Oncotarget 5, 5165 (2014)
- Antidepressant-like properties of novel HDAC6-selective inhibitors with improved brain bioavailability: J. Jochems, et al.; Neuropsychopharmacol. 39, 389 (2014)
Related Products
